We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 877

Sanofi seeks IPR of Cabilly patent
  • Foley & Lardner LLP
  • USA
  • July 30 2015

On July 27, 2015, Sanofi-aventis U.S. LLC and Regeneron Pharmaceuticals, Inc. filed a petition for Inter Partes Review (IPR) of the “Cabilly II”


Biopharma IPR challenges nearly double in 2015
  • Foley & Lardner LLP
  • USA
  • July 28 2015

Newly released statistics (2015-06-30 PTAB Statistics) from the USPTO reveal that the number of biopharma IPR challenges almost doubled in 2015


Biosimilars can sit out patent dance, but may have to wait out second exclusivity period
  • Foley & Lardner LLP
  • USA
  • July 24 2015

In Amgen v. Sandoz, Fed. Cir., No. 15-1499 (July 21, 2015), a divided panel of the Federal Circuit issued its first decision interpreting the


Federal Circuit finds biosimilar patent dispute resoluation procedures optional
  • Foley & Lardner LLP
  • USA
  • July 21 2015

In Amgen v. Sandoz, a divided panel of the Federal Circuit issued its first decision interpreting the Biologics Price Competition and Innovation Act


MSSP final rule adopts all proposed additional program requirements and beneficiary protections provisions
  • Foley & Lardner LLP
  • USA
  • July 21 2015

The Medicare Shared Savings Program (“MSSP”) final rule published on June 4, 2015 finalized all proposed additional program requirements and


Federal Circuit finds biosimilar patent dispute resolution procedures optional
  • Foley & Lardner LLP
  • USA
  • July 21 2015

In Amgen v. Sandoz, a divided panel of the Federal Circuit issued its first decision interpreting the Biologics Price Competition and Innovation Act


Colorado proposes new telehealth rules
  • Foley & Lardner LLP
  • USA
  • July 16 2015

The Colorado Medical Board proposed updated draft guidelines for the delivery of healthcare services via telehealth, as well as remote prescribing


Health care rep and warranty insurance: new solutions for private equity buyers and sellers
  • Foley & Lardner LLP
  • USA
  • July 15 2015

Whether in an auction or proprietary transaction, risk allocation has typically been a function of indemnities tied to reps and warranties and


Can my hospital bill Medicare for telehealth Chronic Care Management?
  • Foley & Lardner LLP
  • USA
  • July 15 2015

In a word: yes, and CMS just introduced proposed rules to clarify the requirements and payment opportunities when hospitals want to bill Medicare for


Congress wows with Medicare Telehealth Parity Act of 2015, but will it succeed?
  • Foley & Lardner LLP
  • USA
  • July 15 2015

Rep. Mike Thompson (D-CA) and co-sponsors Rep. Gregg Harper (R-MS), Rep. Diane Black (R-TN), and Rep. Peter Welch (D-VT) announced, on July 7, 2015